{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:40Z","timestamp":1787027020471,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019971","name":"Luzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2022-JYJ-123"],"award-info":[{"award-number":["2022-JYJ-123"]}],"id":[{"id":"10.13039\/501100019971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this retrospective study, we aimed to identify key risk factors and establish an interpretable model for HCC with a diameter \u2265 5\u00a0cm using Lasso regression for effective risk stratification and clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, 843 patients with advanced hepatocellular carcinoma (HCC) and tumor diameter \u2265 5\u00a0cm were included. Using Lasso regression to screen multiple characteristic variables, cox proportional hazard regression and random survival forest models (RSF) were established. By comparing the area under the curve (AUC), the optimal model was selected. The model was visualized, and the order of interpretable importance was determined. Finally, risk stratification was established to identify patients at high risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Lasso regression identified 8 factors as characteristic risk factors. Subsequent analysis revealed that the lasso-cox model had AUC values of 0.773, 0.758, and 0.799, while the lasso-RSF model had AUC values of 0.734, 0.695, and 0.741, respectively. Based on these results, the lasso-cox model was chosen as the superior model. Interpretability assessments using SHAP values indicated that the most significant characteristic risk factors, in descending order of importance, were tumor number, BCLC stage, alkaline phosphatase (ALP), ascites, albumin (ALB), and aspartate aminotransferase (AST). Additionally, through risk score stratification and subgroup analysis, it was observed that the median OS of the low-risk group was significantly better than that of the middle- and high-risk groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We have developed an interpretable predictive model for middle and late HCC with tumor diameter \u2265 5\u00a0cm using lasso-cox regression analysis. This model demonstrates excellent prediction performance and can be utilized for risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1452201","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:39:40Z","timestamp":1726706380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Construction of an interpretable model for predicting survival outcomes in patients with middle to advanced hepatocellular carcinoma (\u22655\u00a0cm) using lasso-cox regression"],"prefix":"10.3389","volume":"15","author":[{"given":"Han","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000443480","article-title":"Hepatocellular carcinoma extrahepatic metastasis in relation to tumor size and alkaline phosphatase levels","volume":"90","author":"Carr","year":"2016","journal-title":"Oncology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16987","DOI":"10.3390\/ijms242316987","article-title":"Albumin-based liver reserve models vs. MELD 3.0 in prognostic prediction for hepatocellular carcinoma patients with renal insufficiency","volume":"24","author":"Ho","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5694\/mja18.00373","article-title":"Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study","volume":"209","author":"Hong","year":"2018","journal-title":"Med. J. Aust."},{"key":"B7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/jpm12040518","article-title":"Reappraisal of the role of alkaline phosphatase in hepatocellular carcinoma","volume":"12","author":"Huang","year":"2022","journal-title":"J. Pers. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/ajt.12684","article-title":"Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size","volume":"14","author":"Kim","year":"2014","journal-title":"Am. J. Transpl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1038\/s41598-019-40843-9","article-title":"Convergent evolution of copy number alterations in multi-centric hepatocellular carcinoma","volume":"9","author":"Lackner","year":"2019","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13046-019-1412-8","article-title":"Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma","volume":"38","author":"Liu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1478-3231.2006.001285.x","article-title":"Treatment and prognostic factors in patients with hepatocellular carcinoma","volume":"26","author":"Martins","year":"2006","journal-title":"Liver Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion","volume":"156","author":"Munoz-Schuffenegger","year":"2021","journal-title":"Radiother. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2036.2009.04179.x","article-title":"Evolution of prognostic factors in hepatocellular carcinoma in Japan","volume":"31","author":"Nouso","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/lt.20472","article-title":"Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma","volume":"11","author":"Pawlik","year":"2005","journal-title":"Liver Transpl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1159\/000510798","article-title":"Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the soramic trial","volume":"9","author":"Sch\u00fctte","year":"2020","journal-title":"Liver Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","volume":"79","author":"Singal","year":"2023","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JHC.S398632","article-title":"Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram","volume":"10","author":"Su","year":"","journal-title":"J. Hepatocell. Carcinoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1265959","DOI":"10.3389\/fimmu.2023.1265959","article-title":"Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (\u22655 cm): a multicenter experience over a ten-year period","volume":"14","author":"Su","year":"","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2015.07.013","article-title":"Prognostic impact of surgery and radiofrequency ablation on single nodular HCC \u2a7d5 cm: cohort study based on serum HCC markers","volume":"63","author":"Ueno","year":"2015","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1097\/JS9.0000000000000574","article-title":"Neoadjuvant intensity modulated radiotherapy for a single and small (\u22645 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial","volume":"109","author":"Wei","year":"2023","journal-title":"Int. J. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijsu.2016.10.033","article-title":"Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection","volume":"36","author":"Wu","year":"2016","journal-title":"Int. J. Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2015.12.033","article-title":"Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma","volume":"150","author":"Xue","year":"2016","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijsu.2020.06.018","article-title":"Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: a retrospective cohort study in the SEER database","volume":"80","author":"Yan","year":"2020","journal-title":"Int. J. Surg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/liv.15251","article-title":"Changing epidemiology of hepatocellular carcinoma in Asia","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ejso.2008.08.003","article-title":"Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon's role in survival","volume":"35","author":"Zhang","year":"2009","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1452201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:39:41Z","timestamp":1726706381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1452201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1452201"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1452201","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"1452201"}}